F-1: Inspira Technologies Files F-1 for $25M Equity Line

Inspira Technologies Oxy B.H.N. Ltd. filed an F-1 registration statement for the potential resale of up to 24,973,528 ordinary shares by YA II PN, LTD. under a $25.0 million Standby Equity Purchase Agreement.

Summary

• Inspira Technologies Oxy B.H.N. Ltd. (IINN) filed an F-1 registration statement for the resale of up to 24,973,528 ordinary shares by YA II PN, LTD. (YA).
• This filing relates to a Standby Equity Purchase Agreement (SEPA) dated December 12, 2025, which allows Inspira to sell up to $25.0 million of its ordinary shares to YA over a 36-month period at the company's sole option.
• Inspira will not receive any proceeds from the resale of shares by YA, but may receive up to $25.0 million in gross proceeds from direct sales of its ordinary shares to YA under the SEPA.
• YA received a Commitment Fee equal to 2.00% of the Commitment Amount, paid in two tranches of ordinary shares (218,627 shares issued on December 18, 2025, and 245,098 shares to be issued on the 30-day anniversary of the SEPA).
• The purchase price for shares sold to YA under the SEPA will be 97% of the lowest daily VWAP during a three-day period following an Advance Notice.
• Inspira is a specialty medical device company developing life support technology, including the INSPIRA ART system (augmented life support respiratory technology) and the FDA-cleared INSPIRA ART100 system (cardiopulmonary bypass system).
• The company is also developing the HYLA Blood Sensor for real-time blood parameter monitoring.
• As of December 18, 2025, 35,949,247 Ordinary Shares were issued and outstanding; assuming all shares offered are sold to YA and then resold, 60,704,148 Ordinary Shares would be outstanding.
• The company's financial statements for the period ended June 30, 2025, contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• Inspira regained compliance with Nasdaq's minimum bid price requirement by July 17, 2025, after receiving a non-compliance notice on March 10, 2025.

Sentiment

Score: 3

Explanation: While the SEPA provides a potential source of capital, the explicit 'going concern' warning in the financial statements and the substantial potential for shareholder dilution from the equity line and warrants overshadow the positive product development and regulatory clearances. The company's reliance on future capital raises and the inherent risks of operating in Israel further contribute to a cautious outlook.

Positives

• Secured a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. for up to $25.0 million in potential gross proceeds, providing a flexible funding source for working capital and general corporate purposes over 36 months.
• The INSPIRA ART100 system received 510(k) Class II regulatory clearance from the FDA in May 2024 and Israeli AMAR regulatory approval in July 2024.
• First INSPIRA ART100 devices were shipped for deployment to Westchester Medical Center in Valhalla, New York, in December 2024, as part of an evaluation and collaboration.
• The company regained compliance with Nasdaq's minimum bid price requirement by July 17, 2025, after receiving a non-compliance notice on March 10, 2025.
• YA II PN, LTD. and its affiliates are prohibited from engaging in short selling related to Inspira's Ordinary Shares during the term of the SEPA.

Negatives

• The company's financial statements for the period ended June 30, 2025, contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• The SEPA involves potential significant dilution for existing shareholders, as the company may issue up to 24,509,803 new ordinary shares to YA, in addition to 463,725 commitment shares.
• The purchase price for shares sold to YA is at a discount (97% of the lowest daily VWAP), which could lead to sales at prices lower than current market prices, further diluting existing shareholders.
• The actual amount of proceeds from the SEPA is uncertain and depends on market conditions and the company's discretion, meaning the full $25.0 million may not be realized.
• The company will not receive any proceeds from the resale of shares by the Selling Shareholder, only from direct sales to the Selling Shareholder.
• The company expects to still need additional capital even if the full $25.0 million from the SEPA is raised, indicating ongoing funding requirements.
• The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.

Risks

• Uncertainty regarding the actual number of shares sold under the SEPA and the gross proceeds received, which could be substantially less than the $25.0 million commitment.
• Potential for substantial dilution to existing shareholders from future sales and issuances of ordinary shares under the SEPA or other financing activities.
• Sales of a substantial number of ordinary shares in the public market by YA, or the perception of such sales, could depress the market price and increase volatility.
• Investors purchasing shares from YA at different times may pay different prices and experience varying levels of dilution and investment outcomes.
• Need for additional financing to sustain operations, as the $25.0 million from the SEPA may not be sufficient to fully implement the business plan.
• Management's broad discretion over the use of SEPA proceeds, which may not necessarily improve financial condition or market value.
• Risk of delisting from Nasdaq if the company fails to meet listing requirements, which could adversely affect market liquidity and share price.
• Adverse effects on business operations, financial condition, and results due to political, economic, and military instability in Israel, where the company's principal operations are located.
• Disruptions to supply chains and operations due to regional conflicts (e.g., Red Sea attacks, Israel-Iran conflict), although current ceasefires have temporarily reduced immediate risk.
• Potential impact of Israeli military reservist call-ups on employee availability and operations.
• Risk of economic boycotts against Israel and Israeli companies affecting business expansion and operating results.
• Negative impact on the business environment in Israel due to proposed judicial system changes, potentially affecting foreign investment, currency fluctuations, and credit ratings.
• Reliance on forward-looking statements, which are subject to known and unknown risks and uncertainties that may cause actual results to differ materially.
• Inability to retain key executive members.
• Challenges in internally developing new inventions and intellectual property.
• Impact of competition and new technologies.
• Possible impacts of cybersecurity incidents on business and operations.
• Litigation risks.

Future Outlook

The company aims to set a new standard of care for acute respiratory failure, superseding traditional mechanical ventilators with its INSPIRA ART system. It plans to target intensive care units, general medical units, operating theaters, and small urban/rural hospitals globally. The INSPIRA ART system is designed to allow patients to remain awake and avoid intubation, potentially expanding treatment beyond ICU settings. The HYLA blood sensor is being developed for real-time blood parameter monitoring, both integrated and as a standalone device. The company is actively pursuing regulatory approvals and establishing collaborations with strategic partners and globally ranked health centers for endorsement and early clinical adoption.

Management Comments

• "Our goal is to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain spontaneous breathing and avoid the need for intubation, coma and various risks associated with the use of Mechanical Ventilation."
• "The Company believes that the INSPIRA ART may enable treatment of patients without the need for induced coma, intubation or weaning, all of which are associated with incurring the risk of lung infections and lung injury that may prolong hospital admission."
• "We are not obligated to utilize any of the $25.0 million available under the SEPA and there are no minimum commitments or minimum use penalties."
• "We intend to use any proceeds that we receive from sales of our Ordinary Shares to YA under the SEPA for working capital and general corporate purposes."

Industry Context

Inspira Technologies operates in the specialty medical device sector, focusing on life support technology for acute respiratory failure. Its flagship product, INSPIRA ART, aims to disrupt the traditional mechanical ventilation market, which is associated with high risks, costs, and mortality. By offering a non-invasive, awake patient treatment, Inspira seeks to address a significant patient population (up to 20 million annually in ICUs) and potentially expand care settings beyond ICUs. The development of the HYLA blood sensor for real-time monitoring aligns with broader industry trends towards continuous, less invasive patient monitoring and data-driven healthcare. The company's strategy of seeking regulatory approvals and strategic collaborations is typical for medical device companies aiming for market penetration and adoption.

Comparison to Industry Standards

• The INSPIRA ART system aims to supersede traditional mechanical ventilators, which are the current standard of care for acute respiratory failure, by offering a non-invasive approach that avoids intubation and medically induced coma, potentially reducing associated risks, complications, and high costs.
• The INSPIRA ART100 system is an FDA-cleared cardiopulmonary bypass (CPB) system, a known medical industry standard for surgical procedures requiring CPB for six hours or less. Its compact design, extended battery life, and compatibility with various disposable parts offer potential advantages in terms of intra-hospital transfers and inventory management compared to existing CPB systems.
• The HYLA blood sensor is being designed to perform real-time sampling and analysis of blood parameters without the need for blood draws, which could offer a significant improvement over intermittent blood draws, a common practice in critical care settings, by providing continuous monitoring and detecting sudden changes.

Corporate Governance

Related Party Transactions

• Entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. on December 12, 2025, where YA II PN, LTD. is the Selling Shareholder and will purchase shares from the company.
• YA II PN, LTD. received a Commitment Fee of 2.00% of the Commitment Amount, paid in Ordinary Shares, as consideration for its commitment under the SEPA.
• The company paid YA II PN, LTD. a structuring fee of $25,000 in connection with the SEPA.
• On December 12, 2025, YA II PN, LTD. purchased 1,565,217 Ordinary Shares from the company in a registered direct offering at $1.15 per share.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of up to 24,973,528 new ordinary shares under the SEPA. The market price of shares could be depressed by future sales by YA. Investors may pay different prices for shares purchased from YA.
• Employees: Two employees were called up for Israeli military reserve duty as of June 30, 2025, though they have since returned. Future call-ups could disrupt operations.
• Customers/Patients: The development of INSPIRA ART and HYLA blood sensor aims to provide improved life support technology, potentially offering less invasive and more accessible treatment options for acute respiratory failure.
• Creditors: The 'going concern' warning indicates increased risk for creditors. The potential capital raise through the SEPA could improve liquidity, but the need for additional capital suggests ongoing financial vulnerability.
• Suppliers: Disruptions to supply chains due to regional conflicts in Israel could affect the company's ability to manufacture and produce products.

Next Steps

• Continue pursuing regulatory approvals for products.
• Actively work to establish collaborations with strategic partners, globally ranked hospitals, medical device companies, and distributors for endorsement and early clinical adoption.
• Target intensive care units, general medical units, operating theaters, and small urban and rural hospitals for market penetration and adoption.
• File further amendments to the registration statement as necessary to delay its effective date or specifically state its effectiveness.
• Potentially sell additional Ordinary Shares to YA under the SEPA at the company's sole discretion during the 36-month Commitment Period.
• File additional registration statements if more than 24,509,803 Ordinary Shares are to be sold to YA under the SEPA.
• Seek other sources of funding beyond the SEPA to fully implement the business plan.
• Continue internal laboratory testing and hospital collaborations for clinical research for the HYLA blood sensor.

Key Dates

Recommendation

The F-1 filing highlights significant financial distress, explicitly stating 'substantial doubt about our ability to continue as a going concern.' While the Standby Equity Purchase Agreement (SEPA) provides a potential capital infusion, it comes with substantial dilution risk for existing shareholders, as the company can issue up to 24.97 million new shares at a discount to market price. The company also acknowledges that even the full $25 million from the SEPA may not be sufficient for its business plan, indicating a persistent need for further capital. Coupled with geopolitical risks in Israel and the early stage of commercialization for its flagship products, the financial instability and dilution concerns present a high-risk investment profile. A seasoned investor would likely view this as a strong sell due to the fundamental going concern issue and the dilutive nature of the financing.

Keywords

Inspira Technologies, IINN, SEC F-1 filing, Standby Equity Purchase Agreement, SEPA, Equity financing, Dilution, Medical device company, Life support technology, INSPIRA ART, INSPIRA ART100, HYLA Blood Sensor, Acute respiratory failure, Cardiopulmonary bypass, FDA clearance, Nasdaq Capital Market, Emerging growth company, Foreign private issuer, Israel operations, Going concern, Yorkville Advisors Global